Evidence map›Paper›PMID 28217905›Full record

ArticleMicrobial biotechnology2017

Evaluation of Rv0220, Rv2958c, Rv2994 and Rv3347c of Mycobacterium tuberculosis for serodiagnosis of tuberculosis.

Xiaolong You, Ranhui Li, Kanglin Wan, Liangzhuan Liu, Xiaoping Xie, Lanhua Zhao, Ning Wu, Xiangying Deng, Li Wang, Yanhua Zeng

Erratum issuedAbstract readComparative StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  4. A systematic review of potential screening biomarkers for active TB disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2021
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Xiaolong YouInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.
Ranhui LiInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.
Kanglin WanState Key Laboratory for Infectious Disease Prevention and Control/National Institute for communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Liangzhuan LiuInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.
Xiaoping XieClinical laboratory, Hengyang No.1 People's Hospital, Hengyang, 421001, China.
Lanhua ZhaoInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.
Ning WuClinical laboratory, The First Affiliated Hospital of University of South China, Hengyang, 421000, China.
Xiangying DengInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.
Li WangInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.
Yanhua ZengInstitute of Pathogenic Biology, Medical College, University of South China, Hengyang, 421001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB), the leading cause of death among infectious diseases worldwide, is caused by Mycobacterium tuberculosis (M. tuberculosis). Early accurate diagnosis means earlier prevention, treatment and control of TB. To confirm efficient diagnostic antigens for M. tuberculosis, the serodiagnosis value of four recombinant proteins including Rv0220, Rv2958c, Rv2994 and Rv3347c was evaluated in this study. The specificities and sensitivities of four recombinant proteins were determined based on enzyme-linked immunosorbent assay (ELISA) by screening sera from smear-positive pulmonary TB patients (n = 92), uninfected individuals (n = 60) and patients with Mycoplasma pneumoniae (n = 32) that potentially cross-react with M. tuberculosis. The ELISAs showed that Rv0220, Rv2958c, Rv2994 and Rv3347c exhibited high specificities and sensitivities in detecting immunoglobulin G (IgG) antibody, with 98.3/91.3%, 91.7/85.9%, 93.3/89.1% and 93.3/80.4% respectively. According to the receiver-operating characteristic (ROC) analysis, the area under the ROC of the target proteins was 0.988, 0.969, 0.929 and 0.945 respectively. Western blot was established to evaluate the immunoreactivities of target proteins to mice and human sera. Results demonstrated that Rv0220, Rv2958c, Rv2994 and Rv3347c could specifically recognize TB-positive sera and the sera of mice immunized with the corresponding protein. Thus, Rv0220, Rv2958c, Rv2994 and Rv3347c were valuable potential diagnostic antigens for M. tuberculosis.

Indexed as

AnimalsAntibodies, BacterialAntigens, BacterialBlotting, WesternEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin GMiceMycobacterium tuberculosisRecombinant ProteinsROC CurveSensitivity and SpecificitySerologic TestsTuberculosisAntibodies, BacterialAntigens, BacterialImmunoglobulin GRecombinant Proteins

Identifiers

PMID28217905
PMCPMC5404193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.